Rundquist S, Sachs MC, Eriksson C, Olen O, et al. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Aliment Pharmacol Ther 2020 Dec 19. doi: 10.1111/apt.16193.
PMID: 33340426